MoonLake Immunotherapeutics (MLTX) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MoonLake Immunotherapeutics (MLTX) has outperformed Savara (SVRA) over the past year, losing 12.6% versus a loss of 13.4%. Over five years, SVRA leads with a +270.4% price change compared with +12.2% for MLTX. MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $939.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLTX | SVRA |
|---|---|---|
| Share price | $11.07 | $4.26 |
| Market cap | $942.13M | $939.86M |
| 1-day change | +0.36% | -18.23% |
| YTD return | -16.01% | -29.35% |
| 1-year return | -12.63% | -13.41% |
| 5-year return | +12.16% | +270.43% |
| EPS (TTM) | $-3.66 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-227.32M | $-118.84M |
| 52-week high | $23.29 | $7.01 |
| 52-week low | $9.46 | $4.00 |
| Distance from 52-week high | -52.47% | -39.19% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +173.62% | +159.62% |
| Average volume | 1.64M | 2.79M |
| Shares outstanding | 85.11M | 220.62M |
| Employees | 130 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
MLTX vs SVRA FAQ
Which is bigger, MoonLake Immunotherapeutics or Savara?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $939.86M for Savara (SVRA).
Which stock has performed better over the past year, MLTX or SVRA?
MLTX returned -12.63% over the past 12 months, compared with -13.41% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are MoonLake Immunotherapeutics and Savara in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.